Neurology · Philadelphia area, PA
Neurology studies in Philadelphia area, PA
72 recruiting studies have a site in the Philadelphia area. This page includes nearby cities such as Upland, Bryn Mawr, Wynnewood, Abington.
72 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2Overnight stay mentioned
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Vector Y Therapeutics
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
University of Pennsylvania
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingHealthy volunteersEarly Phase 1
Localizing Epileptic Networks Using MRI and iEEG
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Sanofi
- Location
- Plymouth Meeting, PA + 9 other US sites
- Eligibility basics
- Ages 55–85
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Philadelphia, PA + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Rapport Therapeutics Inc.
- Location
- Philadelphia, PA + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Plymouth Meeting, PA + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Bethlehem, PA + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Abington, PA + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Hershey, PA + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Plymouth Meeting, PA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Philadelphia, PA + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Philadelphia, PA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Media, PA + 57 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Philadelphia, PA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Abington, PA + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
- Location
- Philadelphia, PA + 16 other US sites
- Eligibility basics
- Ages 2–55
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Philadelphia, PA + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Philadelphia, PA + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
- Location
- Plymouth Meeting, PA + 22 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Philadelphia, PA + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Philadelphia, PA + 31 other US sites
- Eligibility basics
- Ages 55–90
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.